glaucoma
Conditions
Interventions
Adding topical ripasudil or cosopt ophtalmic solution to prostaglandin analogue.
Using each eye drop for 2 months
Sponsors
Department of Ophthalmology, Toho University Ohashi Medical Center.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who met all of the following inclusion criteria are included:best-corrected visual acuity of at least 15/25,spherical refractie errors between -6.00 and +6.00 diopters,and arefractive cylindrical error within +/-2.00D
Exclusion criteria
Exclusion criteria: Subjects who aren't satisfied with inclusion criteria.Subjects who have a history of intraocular surgery except for cataract. Subjects who have a clinically significant retina-choroidal disease,vitreous disease,or corneal disease.Subjects who have high systolic blood pressure over 150mmHg or high diastolic pressure over 90mmHg at rest.Subjects who are taking Ca blocker,or alpha-1 blocker,or beta-1 blocker,or Sildenafil.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of mean blur rate measured by laser speckle flowgraphy and vessel density measured by OCT angio graphy in optic nerve head and macula after adding each topical. | — |
Countries
Japan
Contacts
Public ContactKyoko Ishida
Department of Ophthalmology, Toho University Ohashi Medical Center. Department of Ophthalmology
Outcome results
None listed